Potential Treatment, ALZ-801, Shows Efficacy in Early Alzheimer’s Patients with Risk Gene

Potential Treatment, ALZ-801, Shows Efficacy in Early Alzheimer’s Patients with Risk Gene
ALZ-801 may be a safe and effective treatment for Alzheimer’s patients with mild disease who carry two copies of the APOE4/4 gene, results of a clinical program indicate. The results are being disclosed in four presentations by the drug’s developer, Alzheon, at the 13th International Conference on Alzheimer’s and Parkinson’s Disease, taking place March 29–April 2 in Vienna. ALZ-801 and its active molecule, tramiprosate,

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *